Sign In
Buy HROW
$33.32
+0.460 (+1.40%)
At Close: Jun 03, 2026
Harrow (HROW) Reports Next Week: Wall Street Expects Earnings Growth
11:01am, Monday, 23'rd Feb 2026
Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Brokerages Set Harrow, Inc. (NASDAQ:HROW) Price Target at $71.43
01:57am, Friday, 20'th Feb 2026
Shares of Harrow, Inc. (NASDAQ: HROW - Get Free Report) have been given an average rating of "Moderate Buy" by the ten ratings firms that are covering the stock, MarketBeat reports. One investment ana
Harrow To Report Fourth Quarter and Year-End 2025 Financial Results After Market Close on March 2, 2026
07:00am, Wednesday, 18'th Feb 2026
NASHVILLE, Tenn., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its finan
Harrow Announces Cash-Pay Direct-to-Prescriber PharmaPack™ Kits
07:00am, Tuesday, 17'th Feb 2026
NASHVILLE, Tenn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the launch of a new Direct-to
Strength Seen in Harrow (HROW): Can Its 9.7% Jump Turn into More Strength?
07:32am, Tuesday, 03'rd Feb 2026
Harrow (HROW) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength dow
Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million, Marking Another Year of Strong Growth
07:00am, Monday, 02'nd Feb 2026
Doubling of VEVYE® Sales Force is On Track, Expansion of IHEEZO® Commercial Footprint to the Office-Based Setting Underway, and Doubling TRIESENCE® Commercial Footprint in the Surgical-Based Sett
Harrow: Revisiting This Eyecare Growth Story Ahead Of Q4 Update
06:06pm, Thursday, 22'nd Jan 2026
Harrow, Inc. continues to execute on its branded ophthalmic portfolio, with Vevye and Iheezo outperforming expectations and gaining market share. Despite a slight Q3 revenue miss and lowered 2025 guid
Harrow: Flirting With Missing 2025 Revised Guidance
12:49pm, Monday, 12'th Jan 2026
Harrow may deliver $265M in 2025 revenue, potentially missing the low end of its revised $270M–$280M guidance. Recent Bloomberg data suggest strong growth in Iheezo and Vevye, but specialty and comp
Harrow, Inc. (NASDAQ:HROW) Receives Consensus Rating of “Moderate Buy” from Analysts
05:45am, Monday, 29'th Dec 2025
Harrow, Inc. (NASDAQ: HROW - Get Free Report) has been given a consensus rating of "Moderate Buy" by the ten brokerages that are currently covering the stock, Marketbeat Ratings reports. One analyst h
Squarepoint Ops LLC Has $640,000 Stock Holdings in Harrow, Inc. $HROW
05:20am, Wednesday, 24'th Dec 2025
Squarepoint Ops LLC decreased its position in Harrow, Inc. (NASDAQ: HROW) by 77.8% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Co
Eye Drops Maker Sets Up After Strategic Buy; Sales Outlook Strong
12:56pm, Tuesday, 09'th Dec 2025
Biotech stock Harrow is in a cup base with a buy point of 50.72 after third-quarter results.
Harrow: Vevye Replaces Xiidra On Tier 1 Formulary At CVS
08:00am, Monday, 01'st Dec 2025
Harrow, Inc. is experiencing explosive growth, driven by its success in branded pharmaceuticals, especially Vevye. Vevye, HROW's flagship dry eye drug, is projected to reach $100M in 2025 and $300M in
Harrow, Inc. $HROW Shares Purchased by Geode Capital Management LLC
04:00am, Saturday, 29'th Nov 2025
Geode Capital Management LLC raised its stake in shares of Harrow, Inc. (NASDAQ: HROW) by 4.7% in the undefined quarter, according to the company in its most recent filing with the Securities and Exch
Private Equity-Style Fund Buys $15.7 Million in Harrow Stock as Revenue Jumps 45%
11:39am, Thursday, 27'th Nov 2025
Philadelphia-based Penn Capital Management added 325,478 shares of Harrow for an estimated $15.7 million in the third quarter. The move created a new position for Penn, which did not report holding an
Harrow to Present at Two Investor Conferences in December
07:00am, Monday, 24'th Nov 2025
NASHVILLE, Tenn., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will particip
